




*In the hands of
Skunk*

**Dr .Marta Di Forti,
MD, MRCPsych
Institute of Psychiatry, London**



Only some « *Dunedin* » cannabis users develop psychosis



L. Arsenaault (Dunedin Study), BMJ, 2002

Schizophrenia spectrum disorder: Cannabis use interacts with genotype

COMT VAL and MET
22q




COMT Val- Met allele frequency
Kidd et al, 2003

"Barack Obama on Weed"

COMT Met-Met



COMT Val-Val



Exposure


∅ Potency

∅ Frequency


∅ Duration



Life-time prevalence of cannabis use among adolescents



Over 40%




Sources: Council of Europe, The ESPAD Report 2003, Nov. 2004

The potency issue




2005-2008 'Effective' Potency Summary




Potter et al 2008 Journal of Forensic Sciences & Home office, 2008

The UK market share of cannabis types 2002-2008




Home office cannabis potency study, 2008

The market share of cannabis types 2002-2008



Home office cannabis potency study, 2008

The market share of cannabis types 2002-2008



Home office cannabis potency study, 2008



South
London

GENETICS and Psychosis (GAP) Study

SLAM: South London and Maudsley
Mental Health NHS Trust

TRUST BOUNDARIES



- 438 subjects in their 1st episode of psychosis (FEP)

Diagnosis defined using the SCAN, (scale for clinical assessment in neuropsychiatry) CEQ-GAP modified version 2008 and 10 hours more assessment ...

- 284 matched healthy controls
(screened for psychosis)

Patterns of Cannabis use in FEP and Controls Table (1)


Pattern of cannabis use	Cases (N =280)	Controls (N =174)	Unadjusted OR	CI 95%
Ever Used				
NO	121 (43.1%)	65 (37.5%)	1.0	-
YES	159 (56.9%)	109 (62.5%)	0.8	0.6-1.5



	Cases N=159	Controls N=109	Unadjusted OR	*Adjusted OR
<i>Duration of Cannabis use</i>				
0-5 years	65 (40.8%)	68 (62.5%)	1	/
6 years and above	94 (59.2%)	41 (37.5%)	2.4	1.8

** age, gender, ethnicity, other stimulants, employment and level of education.*

Frequency X Potency



....and more from GAP

This evening: Poster N 041

“Age at first use of cannabis predict symptoms dimension in 93 first episode psychosis patients”

Arsime Demjaha et al, 2009



Thanks to you & the GAP team



**...and last but
not least:**

Prof.P.Mcguire

Prof.S.Lovestone

Dr.J.Powell

Dr.E. Bramon

Dr. P. Power

And the LEO team

Dr V.Mondelli

Dr.R.Gafoor

Monica Aas

Dr. D.Clifford

Dr. A.Ricciardi

Dr Alice Mule'

B. Freeman

M.Rivera

Sonija Luzi and

The SGDP lab staff